We have shown that the 64Cu-labeled somatostatin receptor 2 antagonist LM3(p-Cl-Phe-cyclo(D-Cys-Tyr-D-Aph(Cbm)-Lys-Thr-Cys)D-Tyr-NH2) exhibits excellent pharmacokinetics, including high tumor uptake and high tumor-to-background ratios when conjugated to the established Cu(II) chelators NODAGA and CB-TE2A [6]. The gene discussed is SSTR2; the disease is neoplasm.